This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Ludwig Institute for Cancer Research Identifier:
First received: June 10, 2004
Last updated: June 15, 2015
Last verified: June 2015

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with progressive small cell lung cancer.

Condition Intervention Phase
Lung Cancer Biological: monoclonal antibody Hu3S193 Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multiple-Dose Targeting Study of hu3S193 in Patients With Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Ludwig Institute for Cancer Research:

Study Start Date: February 2004
Detailed Description:



  • Determine the targeting, tissue distribution, and pharmacokinetics of monoclonal antibody Hu3S193 in patients with progressive small cell lung cancer.


  • Determine the immunogenicity of this drug in these patients.
  • Determine tumor response in patients treated with this drug.
  • Determine the safety of this drug in these patients.

OUTLINE: This is an open-label, pilot study.

Patients receive monoclonal antibody Hu3S193 (MOAB Hu3S193) IV over 30 minutes on day 1 of weeks 1-4. Patients also receive indium In III MOAB Hu3S193 IV over 30 minutes on day 1 of weeks 1 and 4 and then undergo gamma camera imaging. Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed at 1 and 4 weeks, every 3 months for 1 year, and then every 6-12 months thereafter.

PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed small cell lung cancer
  • Progressive disease after 1-3 prior chemotherapy regimens
  • Measurable disease

    • At least 1 measurable lesion ≥ 2 cm that is not in a previously irradiated field
  • Positive immunohistochemical staining for Lewis Y
  • No uncontrolled brain or leptomeningeal metastases



  • 18 and over

Performance status

  • Karnofsky 70-100% OR
  • ECOG 0-1

Life expectancy

  • Not specified


  • WBC ≥ 3,500/mm^3
  • Platelet count ≥ 150,000/mm^3


  • Bilirubin ≤ 2.0 mg/dL
  • INR ≤ 1.3


  • Creatinine ≤ 2.0 mg/dL


  • No clinically significant cardiac disease
  • No New York Heart Association class III or IV cardiac disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Stool guaiac test negative
  • No gastrointestinal bleed within the past 6 months


Biologic therapy

  • No prior mouse monoclonal antibody


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy

Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy


  • Not specified


  • More than 4 weeks since prior participation in any other clinical trial involving another investigational agent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00084799

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)
Principal Investigator: Lee M. Krug, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Chaitanya R. Divgi, MD Memorial Sloan Kettering Cancer Center
  More Information Identifier: NCT00084799     History of Changes
Other Study ID Numbers: CDR0000365621
Study First Received: June 10, 2004
Last Updated: June 15, 2015

Keywords provided by Ludwig Institute for Cancer Research:
recurrent small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on August 16, 2017